Global NASH Congress 2018 - 26th/27th Feb
This upcoming conference in London may be an ideal global forum to release the IMC phase II NASH results. http://www.global-engage.com/event/nash/
Apparently, Yaron Ilan (Immuron's Chief Medical Officer) will be presenting on Monday 26th Feb.
"YARON ILAN Director Department of Medicine, Hebrew University-Hadassah Medical Center, Jerusalem, Israel.
Oral immunotherapy for NASH: A new class of drugs. Targeting the gut immune system for alleviation of the systemic inflammatory response without immune suppression • The systemic immune system plays a role in inflammation and fibrogenesis associated with NASH and has become a potential target for drug development. • Oral immunotherapy is based on targeting components of the gut barrier that serve as a means to alter the immune signals being transported from the gut to the systemic immune system, alleviating the immune-mediated damage in target organs. • Oral immune therapy-based compounds provide an opportunity for immune modulation without immune suppression, with the advantage of being independent of a single molecular/inflammatory pathway. This method of therapy enables targeting all stages of disease. The high safety profile of these drugs make them ideal for long term use, and for using them in combination with other drugs."
